Cargando…
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
Background: Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients' physical status and exercise tolerance and, most importantly, their evol...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438727/ https://www.ncbi.nlm.nih.gov/pubmed/32903594 http://dx.doi.org/10.3389/fonc.2020.01304 |
_version_ | 1783572845991821312 |
---|---|
author | Mallard, Joris Hucteau, Elyse Schott, Roland Petit, Thierry Demarchi, Martin Belletier, Christine Ben Abdelghani, Meher Carinato, Hélène Chiappa, Pascale Fischbach, Cathie Kalish-Weindling, Michal Bousinière, Audren Dufour, Stéphane Favret, Fabrice Pivot, Xavier Hureau, Thomas J. Pagano, Allan F. |
author_facet | Mallard, Joris Hucteau, Elyse Schott, Roland Petit, Thierry Demarchi, Martin Belletier, Christine Ben Abdelghani, Meher Carinato, Hélène Chiappa, Pascale Fischbach, Cathie Kalish-Weindling, Michal Bousinière, Audren Dufour, Stéphane Favret, Fabrice Pivot, Xavier Hureau, Thomas J. Pagano, Allan F. |
author_sort | Mallard, Joris |
collection | PubMed |
description | Background: Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients' physical status and exercise tolerance and, most importantly, their evolution throughout cancer treatment may represent the first step in efficiently counteracting their development with prescribed and tailored exercise training. In this context, the aim of the PROTECT-01 study will be to investigate the evolution of physical status, from diagnosis to the end of first-line treatment, of patients with one of the three most common cancers (i.e., lung, breast, and colorectal). Methods: The PROTECT-01 cohort study will include 300 patients equally divided between lung, breast and colorectal cancer. Patients will perform a series of assessments at three visits throughout the treatment: (1) between the date of diagnosis and the start of treatment, (2) 8 weeks after the start of treatment, and (3) after the completion of first-line treatment or at the 6-months mark, whichever occurs first. For each of the three visits, subjective and objective fatigue, maximal voluntary force, body composition, cachexia, physical activity level, quality of life, respiratory function, overall physical performance, and exercise tolerance will be assessed. Discussion: The present study is aimed at identifying the nature and severity of maladaptation related to exercise intolerance in the three most common cancers. Therefore, our results should contribute to the delineation of the needs of each group of patients and to the determination of the most valuable exercise interventions in order to counteract these maladaptations. This descriptive and comprehensive approach is a prerequisite in order to elaborate, through future interventional research projects, tailored exercise strategies to counteract specific symptoms that are potentially cancer type-dependent and, in fine, to improve the health and quality of life of cancer patients. Moreover, our concomitant focus on fatigue and cachexia will provide insightful information about two factors that may have substantial interaction but require further investigation. Trial registration: This prospective study has been registered at ClinicalTrials.gov (NCT03956641), May, 2019. |
format | Online Article Text |
id | pubmed-7438727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74387272020-09-03 Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol Mallard, Joris Hucteau, Elyse Schott, Roland Petit, Thierry Demarchi, Martin Belletier, Christine Ben Abdelghani, Meher Carinato, Hélène Chiappa, Pascale Fischbach, Cathie Kalish-Weindling, Michal Bousinière, Audren Dufour, Stéphane Favret, Fabrice Pivot, Xavier Hureau, Thomas J. Pagano, Allan F. Front Oncol Oncology Background: Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients' physical status and exercise tolerance and, most importantly, their evolution throughout cancer treatment may represent the first step in efficiently counteracting their development with prescribed and tailored exercise training. In this context, the aim of the PROTECT-01 study will be to investigate the evolution of physical status, from diagnosis to the end of first-line treatment, of patients with one of the three most common cancers (i.e., lung, breast, and colorectal). Methods: The PROTECT-01 cohort study will include 300 patients equally divided between lung, breast and colorectal cancer. Patients will perform a series of assessments at three visits throughout the treatment: (1) between the date of diagnosis and the start of treatment, (2) 8 weeks after the start of treatment, and (3) after the completion of first-line treatment or at the 6-months mark, whichever occurs first. For each of the three visits, subjective and objective fatigue, maximal voluntary force, body composition, cachexia, physical activity level, quality of life, respiratory function, overall physical performance, and exercise tolerance will be assessed. Discussion: The present study is aimed at identifying the nature and severity of maladaptation related to exercise intolerance in the three most common cancers. Therefore, our results should contribute to the delineation of the needs of each group of patients and to the determination of the most valuable exercise interventions in order to counteract these maladaptations. This descriptive and comprehensive approach is a prerequisite in order to elaborate, through future interventional research projects, tailored exercise strategies to counteract specific symptoms that are potentially cancer type-dependent and, in fine, to improve the health and quality of life of cancer patients. Moreover, our concomitant focus on fatigue and cachexia will provide insightful information about two factors that may have substantial interaction but require further investigation. Trial registration: This prospective study has been registered at ClinicalTrials.gov (NCT03956641), May, 2019. Frontiers Media S.A. 2020-08-07 /pmc/articles/PMC7438727/ /pubmed/32903594 http://dx.doi.org/10.3389/fonc.2020.01304 Text en Copyright © 2020 Mallard, Hucteau, Schott, Petit, Demarchi, Belletier, Ben Abdelghani, Carinato, Chiappa, Fischbach, Kalish-Weindling, Bousinière, Dufour, Favret, Pivot, Hureau and Pagano. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Mallard, Joris Hucteau, Elyse Schott, Roland Petit, Thierry Demarchi, Martin Belletier, Christine Ben Abdelghani, Meher Carinato, Hélène Chiappa, Pascale Fischbach, Cathie Kalish-Weindling, Michal Bousinière, Audren Dufour, Stéphane Favret, Fabrice Pivot, Xavier Hureau, Thomas J. Pagano, Allan F. Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol |
title | Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol |
title_full | Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol |
title_fullStr | Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol |
title_full_unstemmed | Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol |
title_short | Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol |
title_sort | evolution of physical status from diagnosis to the end of first-line treatment in breast, lung, and colorectal cancer patients: the protect-01 cohort study protocol |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438727/ https://www.ncbi.nlm.nih.gov/pubmed/32903594 http://dx.doi.org/10.3389/fonc.2020.01304 |
work_keys_str_mv | AT mallardjoris evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT hucteauelyse evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT schottroland evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT petitthierry evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT demarchimartin evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT belletierchristine evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT benabdelghanimeher evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT carinatohelene evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT chiappapascale evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT fischbachcathie evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT kalishweindlingmichal evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT bousiniereaudren evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT dufourstephane evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT favretfabrice evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT pivotxavier evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT hureauthomasj evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol AT paganoallanf evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol |